JP2021527712A - 神経系疾患および障害を、診断、監視、および治療するための方法 - Google Patents

神経系疾患および障害を、診断、監視、および治療するための方法 Download PDF

Info

Publication number
JP2021527712A
JP2021527712A JP2021519529A JP2021519529A JP2021527712A JP 2021527712 A JP2021527712 A JP 2021527712A JP 2021519529 A JP2021519529 A JP 2021519529A JP 2021519529 A JP2021519529 A JP 2021519529A JP 2021527712 A JP2021527712 A JP 2021527712A
Authority
JP
Japan
Prior art keywords
patient
cognitive function
pabra
disease
neurodegenerative disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021519529A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527712A5 (enExample
Inventor
アンソニー ピー． フォード
Original Assignee
キュラセン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュラセン セラピューティクス インコーポレイテッド filed Critical キュラセン セラピューティクス インコーポレイテッド
Publication of JP2021527712A publication Critical patent/JP2021527712A/ja
Publication of JP2021527712A5 publication Critical patent/JP2021527712A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4082—Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring blood gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Developmental Disabilities (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021519529A 2018-06-14 2019-06-14 神経系疾患および障害を、診断、監視、および治療するための方法 Pending JP2021527712A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862685244P 2018-06-14 2018-06-14
US62/685,244 2018-06-14
US201862686654P 2018-06-18 2018-06-18
US62/686,654 2018-06-18
US201962825619P 2019-03-28 2019-03-28
US62/825,619 2019-03-28
PCT/US2019/037371 WO2019241744A1 (en) 2018-06-14 2019-06-14 Methods for diagnosing, monitoring and treating neurological diseases and disorders

Publications (2)

Publication Number Publication Date
JP2021527712A true JP2021527712A (ja) 2021-10-14
JP2021527712A5 JP2021527712A5 (enExample) 2022-06-08

Family

ID=68842373

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021519529A Pending JP2021527712A (ja) 2018-06-14 2019-06-14 神経系疾患および障害を、診断、監視、および治療するための方法

Country Status (6)

Country Link
US (1) US20210251559A1 (enExample)
EP (1) EP3806957A4 (enExample)
JP (1) JP2021527712A (enExample)
AU (1) AU2019287779A1 (enExample)
CA (1) CA3100697A1 (enExample)
WO (1) WO2019241744A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023541379A (ja) * 2020-09-01 2023-10-02 キュラセン セラピューティクス インコーポレイテッド 神経系の疾患及び障害を改善するための組成物及び方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11607395B2 (en) * 2019-12-18 2023-03-21 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
JP7734700B2 (ja) * 2020-06-04 2025-09-05 キュラセン セラピューティクス インコーポレイテッド ベータアドレナリンアゴニストの形態及び組成物
US12616667B2 (en) 2021-11-15 2026-05-05 Curasen Therapeutics, Inc. Compositions and methods for improving neurological diseases and disorders
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
CN120583945A (zh) 2023-01-20 2025-09-02 阿托基公司 用于治疗或预防肌肉消耗的β2-肾上腺素能受体激动剂
GB202302225D0 (en) 2023-02-16 2023-04-05 Atrogi Ab New medical uses
GB202303229D0 (en) 2023-03-06 2023-04-19 Atrogi Ab New medical uses
GB202403169D0 (en) 2024-03-05 2024-04-17 Atrogi Ab New medical uses
WO2025238248A1 (en) 2024-05-17 2025-11-20 Atrogi Ab USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
US9492114B2 (en) * 2004-06-18 2016-11-15 Banner Health Systems, Inc. Accelerated evaluation of treatments to prevent clinical onset of alzheimer's disease
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
US20100216805A1 (en) * 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2716865T3 (es) * 2011-02-18 2019-06-17 Scripps Research Inst Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante
US9320724B2 (en) * 2013-02-13 2016-04-26 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
WO2014152529A2 (en) * 2013-03-14 2014-09-25 Georgetown University Fmri biomarker of neurodegenerative disease
US9889087B2 (en) * 2014-06-10 2018-02-13 The Board Of Trustees Of The Leland Stanford Junior University Intranasal delivery of β2-adrenergic receptor agonists for improving cognition in humans with down syndrome and compositions therefor
WO2017011746A1 (en) * 2015-07-15 2017-01-19 Adm Diagnostics, Llc System and methods for determining a brain condition of a patient sybject to multiple disease states

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023541379A (ja) * 2020-09-01 2023-10-02 キュラセン セラピューティクス インコーポレイテッド 神経系の疾患及び障害を改善するための組成物及び方法

Also Published As

Publication number Publication date
EP3806957A1 (en) 2021-04-21
CA3100697A1 (en) 2019-12-19
US20210251559A1 (en) 2021-08-19
EP3806957A4 (en) 2022-03-16
WO2019241744A1 (en) 2019-12-19
AU2019287779A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
US12558325B2 (en) Methods for improving neurological diseases and disorders
US20210251559A1 (en) Methods for diagnosing, monitoring and treating neurological diseases and disorders
JP2021527711A (ja) 神経系疾患および障害の改善のための方法
ES2327521T3 (es) Procedimientos de prevencion, tratamiento y diagnostico de trastornos de la agregacion de proteinas.
WO2011077733A1 (ja) 経鼻中枢神経系組織標識用組成物、経鼻中枢神経系組織標識用組成物を用いた標識方法及びスクリーニング方法
US20230263749A1 (en) Compositions and methods for improving neurological diseases and disorders
EP2198040B1 (en) In vivo imaging of myelin
US20250134835A1 (en) Compositions and methods for treating patients with amyotrophic lateral sclerosis (als)
US20210251923A1 (en) Methods for improving neurological diseases and disorders
Glaser et al. Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core
US12616667B2 (en) Compositions and methods for improving neurological diseases and disorders
Liao et al. Carbogen inhalation opens the blood-brain barrier in rats without causing long-term metabolic or neurological deficit
WO2024137478A1 (en) Methods for treating various conditions and indications with agonists and antagonists
WO2025188807A1 (en) Combination compositions and methods of use
WO2024137506A1 (en) Compositions and methods for improving neurological diseases and disorders
ES2832549T3 (es) Composiciones y métodos para tratar la esclerosis lateral amiotrófica en respondedores
Salcin Neuroepigenetics of Cocaine Use: A Positron Emission Tomography Study of Histone Deacetylase Expression in People Who Use Cocaine
Leuzy In Vivo Quantification of Glutamatergic Abnormalities in Behavioral Variant Frontotemporal Dementia
Nouriziabari ERP-based detection of brain pathology in rat models for preclinical Alzheimer's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231004

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240305